人工智能赋能冠状动脉微血管疾病病证结合疗效评价体系构建OA
Establishment of AI-enabled Integrated Disease-Syndrome Therapeutic Efficacy Evaluation System for Coronary Microvascular Disease
冠状动脉微血管疾病(CMVD)具有发病率高、诊断率低和远期预后不良的特点.中医药以整体观念和辨证论治为指导原则,治疗CMVD具有整体调节与个体化治疗的独特优势,但受限于疗效评价标准化、客观化等技术和方法难题,亟需建立更完善的疗效评价体系.在智能化、数字化、个体化、精准化的人工智能(AI)技术加持下,心血管疾病的诊疗模式正逐步向精准医疗方向转变.笔者据此提出CMVD病证结合疗效评价体系构建思路与方法,分析AI应用优势及其应用的挑战与对策,为优化CMVD精准管理策略提供理论支撑.
Coronary microvascular disease(CMVD)is characterized by high incidence,low diagnostic rates,and poor long-term prognosis.Guided by the concept of holism and syndrome differentiation and treatment,Chinese medicine(CM)has demonstrated distinctive advantages in treating CMVD through holistic regulation and individualized treatment.However,its application is constrained by methodological challenges in standardizing and objectifying efficacy evaluation,highlighting an urgent need for a more robust assessment system.Empowered by intelligent,digitalized,personalized,and precision-oriented artificial intelligence(AI)technologies,the diagnostic and therapeutic models for cardiovascular diseases are progressively shifting toward precision medicine.Accordingly,this paper proposes the ideas and methods for establishing a therapeutic efficacy evaluation system of CMVD combining disease and syndrome,analyzes the advantages of AI application,along with the associated challenges and countermeasures,aiming to provide theoretical support for optimizing precision management strategies for CMVD.
陶诗怡;于林童;李军;解紫从;谭雨晴;张富渊;黄炫淳;薛甜甜;孟超
中国中医科学院广安门医院心血管科(北京 100053)北京中医药大学东直门医院心血管科(北京 100700)中国中医科学院广安门医院心血管科(北京 100053)中国中医科学院广安门医院心血管科(北京 100053)中国中医科学院广安门医院心血管科(北京 100053)中国中医科学院广安门医院心血管科(北京 100053)中国中医科学院广安门医院心血管科(北京 100053)中国中医科学院广安门医院心血管科(北京 100053)中国中医科学院广安门医院心血管科(北京 100053)
冠状动脉微血管疾病病证结合疗效评价体系人工智能
coronary microvascular diseasecombination of disease and syndrometherapeutic efficacy evaluation systemartificial intelligence
《中国中西医结合杂志》 2026 (8)
982-988,7
中央高水平中医医院临床科研业务费项目(No.HLCMHPP2023065)国家自然科学基金面上项目(No.82474494)国家重点研发计划项目(No.2022YFC3500102)
评论